Elizabeth Eversmann
Nurse Practitioner · Marion, ILNPI 1528051182
Payments from drug & device makers
Across 226 payments — averaging $17.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$948
- Lilly USA, LLC$774
- AstraZeneca$702
- Novo Nordisk$193
- Bayer$190
- Amgen$147
- plus $1K from 24 others
What the payments were for
- Food & beverage$3,88897%
- Education$1003%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 58 | $948 |
| Lilly USA, LLC | 42 | $774 |
| AstraZeneca | 24 | $702 |
| Novo Nordisk | 18 | $193 |
| Bayer | 10 | $190 |
| Amgen | 12 | $147 |
| GSK | 9 | $128 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $113 |
| Boehringer Ingelheim | 6 | $101 |
| Astellas Pharma US Inc | 1 | $100 |
| Pfizer | 4 | $72 |
| Esperion Therapeutics, Inc. | 5 | $68 |
| E.r. Squibb & Sons, L.L.C. | 4 | $67 |
| Biohaven Pharmaceuticals, Inc. | 3 | $39 |
| Sumitomo Pharma America, Inc. | 3 | $38 |
| Novartis | 2 | $37 |
| Harmony Biosciences LLC | 1 | $31 |
| Eisai Inc. | 2 | $29 |
| Axsome Therapeutics, Inc. | 1 | $28 |
| Sunovion Pharmaceuticals Inc. | 2 | $27 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $26 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| Johnson & Johnson | 1 | $18 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Xeris Pharmaceuticals, Inc. | 1 | $14 |
| Exact Sciences | 1 | $13 |
| Merck | 1 | $12 |
| Radius Health, Inc. | 1 | $11 |
| Genentech USA, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,988 in reported general payments places this provider in the 90th percentile of 4,869 nurse practitioner providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 47 | $47,701 |
| MounjaroTirzepatide | 33 | $40,338 |
| OzempicSemaglutide | 31 | $38,183 |
| JardianceEmpagliflozin | 29 | $28,702 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 37 | $23,208 |
| RexultiBrexpiprazole | 12 | $19,602 |
| EliquisApixaban | 25 | $18,020 |
| XareltoRivaroxaban | 14 | $10,874 |
| LinzessLinaclotide | 19 | $10,325 |
| Breo ElliptaFluticasone/Vilanterol | 24 | $9,457 |
| FarxigaDapagliflozin Propanediol | 15 | $8,312 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 17 | $2,477 |
| Esomeprazole Magnesium | 15 | $2,203 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 111 | $1,725 |
| Rosuvastatin Calcium | 101 | $1,340 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $774 | $88,03980 claims |
| Novo NordiskOzempic | $193 | $38,18331 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $128 | $32,66661 claims |
| Boehringer IngelheimJardiance | $101 | $28,70229 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $19 | $19,60212 claims |
| PfizerEliquis | $72 | $18,02025 claims |
| Johnson & JohnsonXarelto | $18 | $10,87414 claims |
| AbbVieLinzess | $948 | $10,32519 claims |
| AstraZenecaFarxiga | $702 | $8,31215 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,869 nurse practitioner providers in Illinois.
Other nurse practitioner in Marion
- Robin DaileyMarion$14K
- Erika VuckoChicago$417K
- Deepa VallikatWest Dundee$332K
- Maria MalotoNaperville$135K
- Valerie LaroyOak Lawn$112K
- Jennifer LiebChampaign$109K
- Tanya MungerRockford$106K
- Kristy LukeChicago$77K
- Yvonna OldakerFlossmoor$74K
- Heather PiercePekin$72K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.